 |
|
|
| |
Bictegravir/FTC/TAF Single-Tablet Regimen in Adolescents: Week-24 Results
|
| |
| |
Reported by Jules Levin
CROI 2018 March 4-7 Boston, MA
Aditya H. Gaur,1 Carina Rodriguez,2 Eric J. McGrath,3 Elizabeth Hellstrom,4 Afaaf Liberty,5 Eva Natukunda,6 Pope Kosalaraksa,7
Kulkanya Chokephaibulkit,8 Sophia R. Majeed,9 Amy Coluci,9 Danielle Porter,9 Pamela Wong,9 Erin Quirk,9 Hiba Graham,9 Cheryl Pikora9
1St. Jude Children's Research Hospital, Memphis, TN; 2University of South Florida Morsani College of Medicine, Tampa, FL; 3Children's Hospital of Michigan, Detroit; 4Be Part Yoluntu Centre, Paarl, South Africa;
5Chris Hani Baragwanath Academic Hospital, Soweto, South Africa; 6Joint Clinical Research Centre, Kampala, Uganda; 7Khon Kaen University, Khon Kaen, Thailand; 8Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand; 9Gilead Sciences, Inc., Foster City, CA
*Comparative tablet sizes of B/F/TAF and integrase inhibitor-containing single-tablet regimens approved in USA for adolescent use; numbers in parentheses are total weights in mg of tablets.
[Note: tablet size is not intended to compare clinical efficacy and safety, indications, dosing regimens, or treatment adherence.]
References
1. Centers for Disease Control and Prevention. HIV Surveillance Report, 2015. http://www.cdc.gov/hiv/library/reports/hiv-surveillance.html;
2. AIDSinfo.
http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf;
3. AIDSinfo. https://aidsinfo.nih.gov/ContentFiles/PediatricGuidelines.pdf;
4. Reisner SL, et al. Top HIV Med 2009;17:14-25;
5. Gallant JE, et al. J Acquir Immune Defic Syndr 2017;75:61-6;
6. Tsiang M, et al. Antimicrob
Agents Chemother 2016.60:7086-97;
7. Descovy [package insert]. Foster City, CA: Gilead Sciences, Inc., April 2016; 8. Genvoya [package insert].
Foster City, CA: Gilead Sciences, Inc., April 2016
|
| |
|
|
|
|
|
